Eberlein; Catherine Anne
Patent Applications and Registrations
Patent applications and USPTO patent grants for Eberlein; Catherine Anne.The latest application filed is for "combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer".
- Eberlein; Catherine Anne - Cambridge GB
- Eberlein; Catherine Anne - Macclesfield GB
- Eberlein; Catherine Anne - Altrincham Cheshire GB
| Patent | Date |
|---|---|
| Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer App 20210177844 - Cross; Darren Anthony Edward ; et al. | 2021-06-17 |
| Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer App 20200237758 - Cross; Darren Anthony, Edward ; et al. | 2020-07-30 |
| TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF App 20120114667 - Eberlein; Catherine Anne ; et al. | 2012-05-10 |
| TARGETED BINDING AGENTS DIRECTED TO a5 1 AND USES THEREOF App 20120107324 - Eberlein; Catherine Anne ; et al. | 2012-05-03 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 